Skip to content

Study · Not a test of the peptide alone · 1997

6 results

Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.

Lissoni P, Cazzaniga M, Tancini G, Scardino E, Musci R, Barni S, Maffezzini M, Meroni T, Rocco F, Conti A, Maestroni G

European urology1 Jan 1997Cited by 25 (Europe PMC)

PMID9076462 (opens in a new tab)DOI10.1159/000474446 (opens in a new tab)PepBankPUB-09076462
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In resistant metastatic prostate cancer, triptorelin plus melatonin reduced PSA by more than 50% in 8/14 patients.

    In plain wordsIn resistant prostate cancer, triptorelin plus melatonin reduced PSA by more than 50% in 8/14 patients.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePSA response greater than 50%
    Study

    n = 14

    Outcome group
    Cancer biomarkers and prognosis · Cancer

    Measurements

    PSA response
    57%
    decrease greater than 50%

    Source sentences

    Summary
    A decrease in PSA serum levels greater than 50% was obtained in 8/14 (57%) patients.
    2 context sentences
    Summary · context
    The study including 14 consecutive metastatic prostate cancer patients with poor clinical conditions (median age: 70.5 years; median PS: 50%), refractory or resistant to a previous therapy with the LHRH analogue triptorelin alone.
    Summary · context
    Triptorelin was injected i.m. at 3.75 mg every 28 days, and MLT was given orally at 20 mg/day in the evening every day until progression, starting 7 days prior to triptorelin.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In resistant metastatic prostate cancer, mean PSA decreased during triptorelin plus melatonin treatment.

    In plain wordsIn resistant prostate cancer, average PSA decreased during triptorelin plus melatonin treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseMean PSA
    Study

    n = 14

    Outcome group
    Cancer biomarkers and prognosis · Cancer

    Source sentences

    Summary
    Moreover, PSA mean concentrations significantly decreased on therapy of triptorelin plus MLT.
    2 context sentences
    Summary · context
    The study including 14 consecutive metastatic prostate cancer patients with poor clinical conditions (median age: 70.5 years; median PS: 50%), refractory or resistant to a previous therapy with the LHRH analogue triptorelin alone.
    Summary · context
    Triptorelin was injected i.m. at 3.75 mg every 28 days, and MLT was given orally at 20 mg/day in the evening every day until progression, starting 7 days prior to triptorelin.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In resistant metastatic prostate cancer, mean prolactin decreased during triptorelin plus melatonin treatment.

    In plain wordsIn resistant prostate cancer, average prolactin decreased during triptorelin plus melatonin treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseProlactin
    Study

    n = 14

    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Mean serum levels of both PRL and IGF-1 significantly decreased on therapy.
    2 context sentences
    Summary · context
    The study including 14 consecutive metastatic prostate cancer patients with poor clinical conditions (median age: 70.5 years; median PS: 50%), refractory or resistant to a previous therapy with the LHRH analogue triptorelin alone.
    Summary · context
    Triptorelin was injected i.m. at 3.75 mg every 28 days, and MLT was given orally at 20 mg/day in the evening every day until progression, starting 7 days prior to triptorelin.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  4. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In resistant metastatic prostate cancer, mean IGF-1 decreased during triptorelin plus melatonin treatment.

    In plain wordsIn resistant prostate cancer, average IGF-1 decreased during triptorelin plus melatonin treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseIGF-1
    Study

    n = 14

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Mean serum levels of both PRL and IGF-1 significantly decreased on therapy.
    2 context sentences
    Summary · context
    The study including 14 consecutive metastatic prostate cancer patients with poor clinical conditions (median age: 70.5 years; median PS: 50%), refractory or resistant to a previous therapy with the LHRH analogue triptorelin alone.
    Summary · context
    Triptorelin was injected i.m. at 3.75 mg every 28 days, and MLT was given orally at 20 mg/day in the evening every day until progression, starting 7 days prior to triptorelin.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  5. 05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In resistant metastatic prostate cancer, 9/14 patients had survival longer than 1 year with triptorelin plus melatonin.

    In plain wordsIn resistant prostate cancer, 9/14 patients survived longer than 1 year with triptorelin plus melatonin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableSurvival longer than one year
    Study

    n = 14

    Outcome group
    Mortality · Cancer

    Measurements

    Survival
    64%
    longer than 1 year

    Source sentences

    Summary
    Finally, a survival longer than 1 year was achieved in 9/14 (64%) patients.
    2 context sentences
    Summary · context
    The study including 14 consecutive metastatic prostate cancer patients with poor clinical conditions (median age: 70.5 years; median PS: 50%), refractory or resistant to a previous therapy with the LHRH analogue triptorelin alone.
    Summary · context
    Triptorelin was injected i.m. at 3.75 mg every 28 days, and MLT was given orally at 20 mg/day in the evening every day until progression, starting 7 days prior to triptorelin.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  6. 06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In patients with prior thrombocytopenia, triptorelin plus melatonin normalized platelet counts in 3/5 patients.

    In plain wordsIn patients with low platelets, triptorelin plus melatonin normalized platelet counts in 3/5 patients.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreasePlatelet normalization
    Study

    n = 5

    Outcome group
    Overall treatment effect · Whole body

    Source sentences

    Summary
    In addition, a normalization of platelet number was obtained in 3/5 patients with persistent thrombocytopenia prior to study.
    2 context sentences
    Summary · context
    The study including 14 consecutive metastatic prostate cancer patients with poor clinical conditions (median age: 70.5 years; median PS: 50%), refractory or resistant to a previous therapy with the LHRH analogue triptorelin alone.
    Summary · context
    Triptorelin was injected i.m. at 3.75 mg every 28 days, and MLT was given orally at 20 mg/day in the evening every day until progression, starting 7 days prior to triptorelin.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.